EIN Presswire | Newsmatics
Techcyte Improves Digital Diagnostic Workflows for Clinical Pathology
News provided byEIN Presswire
Jan 24, 2023, 11:59 AM ET
Techcyte, the developers of the Clinical Pathology AI Platform, improve the flexibility and efficiency of the platform's digital diagnostic workflows.OREM, UTAH, UNITED STATES, January 24, 2023 /EINPresswire.com/ -- Techcyte, the developers of the Clinical Pathology AI Platform, added powerful platform workflow enhancements (profiles and post model processing) to improve the flexibility and efficiency of digital diagnostic workflows for parasitology, bacteriology, hematology, cervical cytology, and bladder cancer surveillance.
All clinical laboratories are facing labor shortages, and the problem is compounded because microscopic analysis can take upwards of 5 to 10 minutes per slide. Techcyte’s new workflow technology saves laboratories time and money by organizing the raw image data presented by the AI into a customizable, efficient workflow that reduces analysis time to 15 to 30 seconds*.
This new post model processing enables medical technologists to apply rules to objects that the algorithms identify. This includes class remapping, dynamic display of classes and objects, semi-quantitative grading, chart display, and ruleset management. The rules can be based on size, morphology, and other attributes associated with each class.
For example, semi-quantitative ranges for the Techcyte peripheral blood smear classifier can be changed for each customer to match their protocols and populations. Band neutrophils can also be graded separately or combined with segmented neutrophils as desired. Sample profiles can also be created to tag samples with percentages in various ranges.
“Our AI is great at analyzing pixels and proposing high confidence targets, but the proposals adapt to the existing workflow to achieve the efficiency gains that labs need,'' said Rick Smith, Techcyte President. “The workflow platform that we have built around our AI algorithms makes Techcyte solutions flexible, efficient, and able to integrate with lab information systems to better meet our customers’ needs.
Techcyte’s parasitology, bacteriology, hematology, cervical cytology, and bladder cancer surveillance products are currently for Research Use Only in the U.S.
*This claim has not yet been examined by the FDA. (https://jcm.asm.org/content/58/6/e02053-19)
Techcyte, Inc. was founded in 2013 in Orem, Utah and is the world leader in AI-based cellular digital diagnostics. Techcyte’s Clinical Pathology AI Platform uses deep machine learning to perform automated analysis of whole slide microscopy images, revolutionizing digital diagnostics for human, animal, and environmental clinics and labs.
Visit techcyte.com for more information.
Techcyte’s clinical pathology platform is for Research Use Only in the United States.